Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment

NCT06766266 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Non-Muscle Invasive Bladder Urothelial Carcinoma

Interventions

DRUG: Irinotecan liposome II combination therapy regimen
DRUG: Irinotecan liposome II combination therapy regimen

Sponsor

First Affiliated Hospital of Chongqing Medical University